FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression
Go back to FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression| (NASDAQ: GTHX) | Delayed: 3.86 -0.13 (3.26%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.99 | 52 Week High | $ | |||
| Open | $3.93 | 52 Week Low | $ | |||
| Day High | $3.93 | P/E | N/A | |||
| Day Low | $3.77 | EPS | $ | |||
| Volume | 538,169 | |||||
